What the FDA labels say about taking them together
Carbamazepine and lurasidone
Lurasidone's FDA label of January 31, 2025 names carbamazepine in its contraindications section; carbamazepine's label does not name lurasidone itself but warns about its class (Atypical antipsychotics). The lurasidone label: “Concomitant use of LATUDA with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of LATUDA alone.”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the lurasidone FDA label on DailyMed (effective January 31, 2025, Sumitomo Pharma America, Inc.).
What does the carbamazepine label say about lurasidone?
Carbamazepine's label does not name lurasidone itself; it warns about its class (Atypical antipsychotics):
Carbamazepine label, drug interactionsCNS Depressants The concomitant use of Carbatrol and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the lurasidone label say about carbamazepine?
Lurasidone label, contraindicationsStrong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Drug Interactions ( 7.1 )].
Lurasidone label, drug interactionsStrong CYP3A4 Inducers Clinical Impact: Concomitant use of LATUDA with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of LATUDA alone. Intervention: LATUDA should not be used concomitantly with strong CYP3A4 inducers [see Contraindications ()]. Examples: Rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine
Source: FDA drug label (Latuda), NDA200603 (Sunovion Pharms Inc), as published by Sumitomo Pharma America, Inc., effective January 31, 2025 (SPL set afad3051-9df2-4c54-9684-e8262a133af8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Lurasidone | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Schizophrenia, Bipolar disorder, Depression |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | $0.142 per tablet 20 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once